PRESS RELEASE
AB SCIENCE ANNOUNCES THAT IT HAS RECEIVED NEW AUTHORIZATIONS TO RESUME PATIENT ENROLLMENT IN ITS PHASE 3 STUDIES OF MASITINIB, CONFIRMING A GLOBAL RESUMPTION OF THESE STUDIES
These authorizations follow the validation in
These authorizations follow those already received from European agencies [2], in amyotrophic lateral sclerosis (
[1] Press release dated
[2] Press releases of
About amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disorder that is characterized by progressive loss of the upper and lower motor neurons at the spinal or bulbar level. The disease belongs to a group of disorders known as motor neuron diseases, which are characterized by the gradual degeneration and death of motor neurons. In ALS, both the upper motor neurons and the lower motor neurons degenerate or die, and stop sending messages to muscles.
The prevalence of ALS in western countries is fairly uniform at 6 per 100,000 persons, corresponding to around 30,000 cases in
The first drug treatment for ALS, riluzole (Rilutek), was approved in 1995. In
About indolent systemic mastocytosis
Indolent systemic mastocytosis (ISM) is a hematological disease characterized by an abnormal number and activation of mast cells in the bone marrow and other organs. The disease if characterized by multiple symptoms that are disabling and can in some cases be life-threatening. Symptoms associated ISM are predominantly associated with neurological disorders (depression, fatigue, cognitive impairment, headache), skin disorders (pruritus, skin lesions), flushing and gastro-intestinal disorders. ISM affects approximately 40,000 people in
About masitinib
Masitinib is a orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.
About
Founded in 2001,
Further information is available on AB Science’s website:
www.ab-science.com.
Forward-looking Statements -
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.
These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While
For additional information, please contact:
Financial Communication & Media Relations
investors@ab-science.com
Media Relations –
RooneyPartners
kbarrette@rooneyco.com
+1 646 432 0191
Media Relations –
NewCap
Arthur Rouillé
arouille@newcap.fr
+33 (0)1 44 71 00 15
Attachment
- Reprise recrutement global VEng VF
Source:
2021 GlobeNewswire, Inc., source